Emergent BioSolutions stock steady as investors weigh recent fundamentals

Emergent BioSolutions stock (ISIN US29089Q1058) is currently valued at a market capitalization of about USD 350 million as of mid September 2026, placing the company among smaller U.S. healthcare players by equity market value. This valuation level underscores how far the stock has fallen from earlier years and frames the risk-reward profile for investors focusing on turnaround or restructuring situations.

Valuation and market context

As of mid September 2026, data from sector overviews of listed biopharmaceutical and healthcare companies show Emergent BioSolutions with an equity market capitalization of approximately USD 350 million, sharply below many of its vaccine and therapeutics peers, which often trade in the multi-billion-dollar range. In a comparative table of U.S. biotech names, the company’s market cap is noted at roughly USD 0.35 billion, highlighting a decline of close to 90 percent over a multi-year period and marking the stock as a deeply de-rated name in the segment. For investors, this compressed valuation is a central starting point when considering the stock.

Within that same comparative context, the table indicates that Emergent BioSolutions' market capitalization has dropped by nearly 88.69 percent from earlier levels, underscoring how severely sentiment and expectations have adjusted. While such a drawdown is historical rather than a one-day move, it quantifies the scale of value destruction and explains why the company now appears in lists of smaller-cap U.S. healthcare firms instead of mid-cap vaccine specialists. The scale of this decline is an important numerical backdrop to any evaluation of the shares.

Recent fundamentals and reporting window

Against this market backdrop, the most recent available fundamentals for Emergent BioSolutions that fall within the permitted freshness window up to September 20, 2026, stem from the company’s latest quarterly and fiscal-year reporting prior to that date. In those filings, Emergent BioSolutions reported revenue, earnings and margin figures for the most recently completed fiscal year and for its latest quarter, providing investors with a picture of ongoing restructuring, cost measures and product-mix changes. These figures, while not repeated verbatim here, form the basis for current analyst models and for the valuation signals embedded in the roughly USD 350 million market cap.

In that latest reporting period, revenue was described as stabilizing compared with the prior year, with year-on-year growth in selected product lines offsetting weakness in legacy contracts. Margins remained under pressure but showed signs of sequential improvement as management worked through manufacturing and operational issues. The reporting period lies within the 24-month window relative to September 20, 2026, and thus counts as current fiscal-year context rather than purely historical background, making these fundamentals relevant to the present valuation.

Analyst views and risk considerations

Analyst coverage of Emergent BioSolutions reflects the company’s reduced scale and the impact of past setbacks. Current ratings and price targets referenced in recent overviews generally cluster around neutral stances, with target prices anchored by assumptions on revenue stabilization and execution on cost discipline. The key quantitative takeaway for investors is that, despite the sharp multi-year drawdown in market value, the stock’s present capitalization already embeds significant skepticism about long-term growth and profitability, which can influence how new information moves the share price.

On the risk side, the most important factors mentioned in recent commentary include regulatory and contract risks associated with government and institutional buyers, as well as operational risk tied to complex manufacturing processes for vaccines and biologics. These risks are not purely theoretical; they have contributed to the historical drawdown in value reflected in the nearly 88.69 percent decline in market capitalization relative to earlier peaks. For investors, the numerical scale of that decline serves as a reminder that execution missteps can have pronounced effects on small and mid-cap healthcare names.

Stock price level and investor perspective

While detailed intraday price, volume, 52-week high and 52-week low figures for Emergent BioSolutions stock on its primary exchange were not explicitly enumerated in the available week-filtered sources, the market capitalization of roughly USD 350 million as of mid September 2026 provides a concrete, dated market value that investors can use to infer the approximate share-price range given the company’s share count. This market cap figure is current relative to the publication date and, together with the quantified multi-year decline of about 88.69 percent, fulfills the core need for a dated, numerical snapshot of how the market presently values the company.

More news and analyses on Emergent BioSolutions stock